When considered as continuous variables, every 1-unit increase in serum RCAN2 levels was associated with 20.1, 19.3, 19.9, 18.9, and 17.5% increase, respectively, in risk of NAFLD prevalence in Model 1–5. The gene discussed is RCAN2; the disease is metabolic dysfunction-associated steatotic liver disease.